Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 PUFA for Antenatal Major Depressive Disorder
NCT03101540Phase 1Terminated
- Start
- Aug 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of eicosapentaenoic acid and docosahexaenoic acid in major depressive disorder (MDD). Primary endpoint: Hamilton Rating Scale for Depression. Started Aug 2011; status: terminated.
02
Drugs
eicosapentaenoic aciddocosahexaenoic acid
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03101540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101540.